Chloe Evelyn Atreya, MD, PhD, and Axel Grothey, MD, on Efficacy of Targeted Treatments in BRAF-Mutated Metastatic Colorectal Cancer
2015 ASCO Annual MeetingChloe Evelyn Atreya, MD, PhD, of the University of California, San Francisco, talks with Axel Grothey, MD, of the Mayo Clinic, about new data on trametinib, dabrafenib, and panitumumab in patients with the BRAF V600E mutation and vemurafenib plus irinotecan and cetuximab in BRAF-mutated metastatic colorectal cancer (Abstracts 103 and 3511).
Related Videos
Areej El-Jawahri, MD, and Eric Roeland, MD, FAAHPM, on Quality of Life and Satisfaction With Care
Eric Roeland, MD, FAAHPM, of the University of California, San Diego Moores Cancer Center, and Areej El-Jawahri, MD, of Massachusetts General Hospital, discuss two...
Andrew Zelenetz, MD, PhD's Expert Analysis of Two Key Lymphoma Trials: FLASH and GADOLIN
Andrew Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses two important lymphoma trials presented at ASCO and his views on whether their results are indeed pra...
Howard M. Sandler, MD, Summarizes Results of the RTOG 0521 Trial on Localized, High-Risk Prostate Cancer
Howard M. Sandler, MD, of Cedars-Sinai Medical Center discusses the improvement of overall survival with the use of adjuvant chemotherapy following androgen suppression and radioth...
Jedd Wolchok, MD, PhD, Summarizes Results From the CheckMate 067 Trial in Advanced Melanoma
Jedd Wolchok, MD, PhD, of Memorial Sloan Kettering Cancer Center discusses therapies for treatment-naive patients with advanced melanoma (
Ruben A. Mesa, MD, of the Mayo Clinic, discusses pacritinib and its significant efficacy in myelofibrosis (
Ruben A. Mesa, MD, Summarizes Results of the PERSIST-1 Study on Myelofibrosis
